Purpose: Respiratory papillomas, caused by human papillomaviruses types 6 and 11 (HPV6/11), are premalignant lesions with potential for malignant conversion. The cytokine and chemokine micromilieu of papillomas is T H 2-like with a marked absence of IFN-g expression. To illuminate why patients with recurrent respiratory papillomatosis (RRP) fail to effectively control their disease, we further investigated the suppressive cellular microenvironment in papillomas.
Introduction
Recurrent respiratory papillomatosis (RRP) is characterized by the relentless recurrence of laryngeal papillomas that are induced by human papillomavirus (HPV) types 6 and 11. Laryngeal papillomas are premalignant lesions with potential for malignant conversion. This rare disease has an estimated incidence in the United States of 4.3/10 5 in children less than 14 years old, and of 1.8/10 5 in adults. The estimated cost of surgical treatment for RRP in the United States is greater than 100 million USD per year (1) .
The strategic location of these lesions in the larynx and upper airway causes significant morbidity and, on occasion, mortality. Patients with severe disease can require more than 150 general surgeries under general anesthesia to maintain a patent airway. The interval between surgical interventions can vary between patients ranging from 3 weeks to several years. Laryngeal disease can spread to the lower respiratory tract, and on occasion RRP can progress to malignancy (1, 2) .
The persistent recurrence of HPV6/11 infection in these lesions highlights the failure of RRP patients to generate effective HPV-specific, innate and/or adaptive immune responses, although they show normal immune homeostasis, and respond normally to other infectious microbes (1) . Thus, a better understanding of the HPV-specific, T-cell dysfunction in RRP that supports chronic HPV infection of laryngeal keratinocytes could provide a rationale to develop nonsurgical strategies that would correct this defect.
Previously we described RRP as a T H 2-like disease that is characterized by an imbalance in T H 1-/T H 2-like cytokine and chemokine expression (1) (2) (3) . We identified a correlation between RRP disease severity and the expression of select class II MHC genes that likely regulate this imbalance (1) (2) (3) (4) and predispose HPV6/11-infected individuals to develop RRP (1, 4) . Recently, we described differences in the repertoire of killer cell immunoglobulin-like receptor (KIR) gene haplotypes in RRP as compared with controls (1) . In addition, we also identified natural killer cell dysfunction in RRP (1) and differential expression of T H 2-like polarizing immune response genes in papillomas compared with autologous unaffected laryngeal tissue (1, 5) .
The objective of this study was to further characterize the repertoire of T-cell subpopulations within tissue-infiltrating lymphocytes (TIL) from respiratory papillomas that support chronic HPV6/11 infection in these lesions.
In this article, we provide evidence for the first time that there is an enrichment of functional CD3
low/À regulatory T cells (Treg; ref. 6 ) that infiltrate HPV6/11 induced, respiratory papillomas. We also identified the two chemokines (CCL17 and CCL22) that recruit Tregs into tissues where they are expressed (7) . In addition, we show that the majority of CD4 þ
Foxp3
À TILs (non-Tregs) in papillomas express a surface phenotype that is characteristic of exhausted T cells (PD1
; refs. 8-10), suggesting that this major T-cell fraction is chronically activated, quiescent, and unable to produce effector cytokines in response to these HPVs. Furthermore, we provide evidence that the PD-1/PD-L1 pathway (11) is likely active in RRP, given that papilloma-derived TILs express PD-1 strongly, and that papilloma tissue robustly expresses PD-L1, compared with control-derived laryngeal tissues. Taken together, these mechanisms may contribute to the immunosuppressive microenvironment in papillomas that prevent HPV-specific, effector T H 1-like T-cell function in RRP.
Materials and Methods

Subjects and index of disease severity
Thirty-seven randomly selected patients with RRP with varying disease severity were studied. Before enrollment, all patients signed informed consent that was approved by the Institutional Review Board at the North Shore-LIJ Health System. Table 1 shows the demographics of all patients with RRP included in this study.
Heparinized blood and biopsies of autologous respiratory papillomas were obtained during surgical intervention. HPV typing was carried out as previously described in detail (3, 12) . Disease severity is defined by a composite score that represents the extent of disease and is inversely proportional to the frequency of recurrence (1). The composite score was used to define the overall severity for an individual patient. Three or more surgeries in the previous 12 months with a
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Isolation of PBMCs and CD4
þ T regulatory cells from respiratory papillomas and peripheral blood Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque Plus gradient centrifugation (GE Healthcare). These PBMCs were stained for surface and intracellular markers, or used as responders in the in vitro suppression assay described below. TILs were isolated from fresh papilloma biopsies by mechanical dissociation, and the resulting cell suspension was passed through a 70-micron mesh filter. Tregs were isolated from TILs using a Aliquots of the sort purified T-cell subpopulation were cocultured with autologous PBMCs in the suppression assay described below.
Antibody staining and flow cytometric analyses
PBMCs and TILs were washed in PBS containing 2% FBS and 0.1% sodium azide and surface stained for Tregs using the following combinations of directly conjugated antibodies: anti-CD4 PerCP, anti-CD25 FITC, and anti-CD127 PE (BD Biosciences). After washing, cells were stained for intracellular FoxP3 (anti-FoxP3-APC, clone PCH101, eBioscience) using the manufacturer's recommended procedure. Stained and washed cell suspensions were resuspended in 1% formaldehyde. Additional specimens were stained for surface expression with anti-PD-1 APC or PECy7, anti-PD-L1 PE, anti-CD69 PE, (BD Biosciences), or intracellular anti-Helios PE, (Biolegend).
Samples H-thymidine was added to each well for the last 18 hours of incubation. Plates were harvested as previously described (14) . The proliferative responses were expressed as mean 3 H-thymidine incorporated counts per minute (CPM) of triplicate wells minus background.
mRNA expression of CCL17, CCL22, and programmed cell death ligands, PD-L1 and PD-L2
To determine whether papillomas expressed CCL17 and CCL22, known to be chemoattractants for Tregs (7), or expressed PD-L1 (CD274) and/or PD-L2 (CD273), the ligands for PD-1 (CD279; ref. 11), we determined the relative expression of these genes by quantitative realtime reverse transcriptase PCR (qRT-PCR). Relative levels of mRNA from papillomas (PAP, n ¼ 9), clinically normal laryngeal tissues from RRP patients (normal adjacent, NA, n ¼ 11), and controls without RRP (true normal, TN, n ¼ 6) were determined. Briefly, total RNA was isolated using nucleic acid affinity spin columns (Qiagen) together with DNase-1 digestion. I-Script One-step RT-PCR for Probes (BioRad) was done on an Applied Biosystems 7900HT thermocycler with gene-specific, intron-spanning, primers and either the appropriate FAM-labeled probe from the Universal Probe Library (Roche) or a FAM/TAMRA custom TaqMan probe (Supplementary Table) . The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the input RNA. mRNA expression of CCL17, normalized to GAPDH, was calculated relative to the mean NA tissue, using the DDC T method (5) . Similarly, mRNA expression of PD-L1 and PD-L2, normalized to GAPDH, was calculated relative to TN PD-L1 expression. The expression efficiency of the PD-L1 and PD-L2 probe/primer sets were linearly efficient among the range of cycles measured in this assay, allowing for cross-primer relative expression calculations. Data from each group had similar SDs, confirmed by the method of Bartlett, and were Gaussian distributed, confirmed by the method of Kolmogorov and Smirnov. Therefore ANOVA was used to analyze the 3 groups (TN, NA, and PAP), and a Turkey-Kramer multiple comparison test and 2-tailed unpaired t tests were done to compare between 2 groups.
Statistical analysis
All statistical analysis employed a 2-tailed, unpaired t test done by InStat (GraphPad). When the data was not normally distributed, it was log-transformed, and if the SD was different between groups, a Welch correction was applied.
Results
The frequency of Foxp3 þ CD127 low/À Tregs are increased in CD4 þ T cells from papillomas compared with blood of patients with RRP The flow cytometric strategy for identifying Tregs within TILs from a respiratory papilloma, and from the blood of the same patient, is shown in Fig. 1 Tregs isolated from papilloma TILs function by suppressing PBMC proliferation The functional capacity of Tregs isolated from TILs was determined using an in vitro micro coculture suppression assay (Fig. 2E) . CD25 þ CD4 þ cells, enriched by magnetic bead selection from the papillomas of patients with RRP, were cocultured with anti-CD3 and anti-CD28 activated, autologous PBMCs. There was marked suppression of PBMC proliferation (66% AE 11.8%) when autologous Tregs, enriched from TILs, were added. In contrast, when autologous, additional blood-derived CD4 þ T cells were added back as a control to similarly activated PBMCs, proliferation was enhanced. The mean AE SD suppression ratios were calculated by dividing the CPM of PBMCs alone (black bars), by the CPM of PBMCs with added TILs (light grey bars), or by the CPM of PBMCs with added autologous CD4 cells (grey bars; Fig. 3E ). Using these ratios, the TILs markedly suppressed PBMC proliferation (À3.3 AE1.3), whereas the autologous CD4 cells did not (1.5 AE 0.4; P ¼ 0.0033).
Treg-attracting chemokine CCL17 is differentially expressed by papillomas To determine whether the increase of Tregs in papillomas was the result of the expression of chemokines known to attract Tregs into tissues (18), we compared CCL17 and CCL22 mRNA expression in 9 papillomas (PAP), 11 clinically normal laryngeal tissues from RRP patients (NA), and 6 control laryngeal tissues (TN) from patients without RRP (Fig. 3) . All 3 types of tissues expressed equivalent amounts of CCL22 mRNA (data not shown). In contrast, the expression of CCL17 mRNA was upregulated in papillomas, compared with both types of control laryngeal tissues (Fig. 3) . Thus, Tregs may be recruited to papillomas by CCR4 receptor engagement of an increasing gradient of CCL17 that is differentially 
CD127
low/À cells in the CD4 þ T-cell populations from papilloma tissues (TILs; black bars, 25.0% AE 8.0% and 19.5% AE 6.7%, respectively), and autologous blood (grey bars, 7.3% AE 1.8% and 7.8% AE 1.8%, respectively) was determined by flow cytometry. Both populations were significantly increased in the tissue when compared with autologous blood (n ¼ 17, P < 0.0001, unpaired t test with Welch correction). B, percent of CD4
low/À Tregs with reduced CD25 levels was 46.9% AE 13.5% in papilloma tissues (TILs) and 13.4% AE 5.5% in the blood of patients with RRP (n ¼ 17, P < 0.0001, unpaired t test with Welch correction). C and D, Helios expression on CD4þ T cells isolated from laryngeal papilloma tissue and autologous blood. C, the composite results of 6 patients with RRP. Bright expression of Helios was detected on 66.1% AE 6.5% of Tregs isolated from the blood and on 31.2% AE 18.5% of papilloma-derived Tregs, P < 0.005, 2-tailed t test. D, representative example of Helios expression on CD4
low/À T cells. High expression of Helios was detected on 61.47% and 38.93% of Tregs isolated from blood and tissue, respectively. E, Tregs enriched from papilloma-derived TILs suppress PBMC proliferation. PBMCs (black bars) were cultured alone or with Tregs isolated from papilloma tissue (light grey bars), or with autologous CD4 þ cells isolated from PBMCs (grey bars). Suppression of PBMCs proliferation by Tregs was observed in all 3 patients studied (76%, 53%, and 69%, respectively, light grey bars), whereas control PBMC cultures with added autologous CD4 þ T cells showed an anticipated increase in proliferation (grey bars).
expressed by papillomas, together with normal constitutive robust expression of CCL22. and had low or absent expression of CD127 (49.2% AE 7.4%; Fig. 4 ). In comparison, the majority of CD4 þ nonTregs in the blood were CD127 þ , and only a minor subgroup of these cells lacked CD127 (22.2% AE 5.4%, P < 0.001). CD127 is constitutively expressed on naive T cells, is downregulated upon T-cell activation, and then reexpressed on a subset of effector T cells that ultimately differentiate into memory T cells (19) . The absence of CD127 expression on T cells has been associated with Tcell exhaustion in patients with chronic infection or tumors (8, 19) , whereas absent CD127, Foxp3, and CD25 expression is also a characteristic of effector Tr1-like cells (20, 21) . Therefore we asked whether this major T-cell subpopulation in TILs (CD4 þ CD25 low/À CD127 low/À ) could also suppress PBMC proliferation. This purified Figure 3 . Differential CCL-17 mRNA expression in laryngeal tissues. Total mRNA from laryngeal tissue obtained from true normal tissues (TN), clinically normal adjacent laryngeal tissue (NA) from patients with RRP, and from respiratory papillomas (PAP) were compared using real-time RT-PCR, and expressed as a relative mRNA concentration (DDCt), after being normalized to a housekeeping gene (GAPDH), and also standardized to NA tissue. Papilloma (PAP) CCL-17 mRNA expression was increased between groups (P < 0.02, ANOVA) and between NA and PAP (P ¼ 0.01, t test). T cells from the blood of a control without RRP showed 40% suppression of autologous PBMC proliferation. Thus, CD4 þ CD25 low/À CD127 low/À T cells in control blood contain a subpopulation of functional Tr1-like effector cells, as described (6, 20, 21) , whereas T cells with this phenotype in TILs from papillomas do not contain sufficient Tr1-like cells to show suppression in vitro.
PD-1 and CD69 are highly expressed on TILs from papillomas
To determine whether the PD-1/PD-L1/L2 pathway was relevant in the immunosuppressive micromilieu present in papillomas, TILs from 7 patients were stained with anti-PD-1 antibodies and analyzed by flow cytometry. PD-1 was expressed on 85% AE 7% of the CD3 þ T cells and on 92% AE 4% of CD4 þ T cells from these papillomas (Fig. 5A ). In addition, the intensity of expression of PD-1 on TILs was much greater than that observed on T cells from the blood. The majority of TILs also expressed CD69, another marker of activation (9) . These results suggested that the CD4 þ effector T cells within papilloma TILs are chronically activated as continuous engagement of the TCR is necessary for maintaining a high PD-1 expression (9). The majority of TILs did not express CD25 and therefore they may be in an exhausted state with reduced capacity to proliferate and produce cytokines, as has been shown for CD8 þ PD-1 þ T cells during chronic infection (10) . Thus, in addition to the decreased CD127 expression that was observed on the majority of CD4 þ TILs, the papilloma microenvironment also contributes to effector dysfunction by upregulating PD-1 expression on T cells.
PD-L1 and PD-L2 are expressed by papillomas
To determine whether the engagement of PD-1 that is highly expressed on the majority of CD3
þ TILs could represent a mechanism that induces T-cell exhaustion in papillomas, we analyzed PD-L1 and PD-L2 mRNA extracted from papilloma tissue, clinically normal laryngeal tissue, and control laryngeal tissues from individuals without RRP. PD-L1 mRNA in papillomas (PAP, n ¼ 9) was relatively expressed 145 times more than laryngeal tissues from individuals without RRP (TN, n ¼ 6) and 93 times more than clinically normal laryngeal tissues from RRP patients (NA, n ¼ 11; P < 0.0001 ANOVA and P < 0.0001 unpaired 2-tailed t test for TN vs. NA, and TN vs. PAP; Fig. 5B ). In contrast, all 3 types of laryngeal tissues expressed PD-L2 mRNA equivalently and at relative expression levels of 15 to 32 times that of PD-L1 in TNs. Thus, PD-1 ligation on CD3 þ TILs by PD-L1 expressed by papillomas may represent an additional inhibitory pathway that blocks effector T-cell function in these lesions as previously reported in other systems (8) .
Discussion
There has been intense interest in the role of Tregs and their respective subpopulations in both murine and human disease. Increased Treg numbers and function have been A, TILs and autologous PBMCs were stained with antibodies to CD3, CD4, and CD69 (row 1), or CD3, CD4, CD127, Foxp3, and PD-1 (rows 2 and 3). Representative samples from 2 patients with RRP (row 1, patient 1; rows 2-3, patient 2) are shown. Gating was done using CD3 þ T cells (rows 1 and 2) and CD3
. B, total mRNA normal laryngeal tissue from individuals without RRP (TN; n ¼ 6), clinically normal adjacent laryngeal tissue from patients with RRP (NA; n ¼ 11), and from respiratory papillomas (PAP; n ¼ 9) were compared using real-time RT-PCR. Relative mRNA expression (DDC t ), was normalized to GAPDH mRNA, a housekeeping gene, and standardized to PD-L1 TN. PD-L1 was upregulated in both NA and PAP compared with TN (P < 0.0001, ANOVA and post hoc t tests). There was no significant difference in PD-L2 mRNA levels between the 3 different laryngeal tissues. linked to chronic bacterial, parasitic, and viral (HIV, HCV, and EBV) infection, whereas a low frequency and/or reduced Treg function have been linked to the resolution of acute infection and the reestablishment of tumor immunity in various cancers, as recently reviewed (22) . Most relevant to our studies are recent descriptions of Tregs in chronic HPV infection of the human cervix, specifically cervical intraepithelial neoplasia and cervical cancer caused by HPV16 and 18. These studies showed that the frequency of Tregs increased with HPV-induced cervical disease (23, 24) . In this article, we provide evidence for the first time that there is an increased frequency of functional Foxp3
low/À Tregs within the total CD4 þ TIL population in HPV6/11-induced respiratory papillomas. The frequency of these Tregs within respiratory papillomas did not predict disease severity, unlike that reported in cervical neoplasia (23, 24) . Thus, an increased frequency of functional Tregs likely contributes to the chronicity of HPVinduced RRP, but may not greatly influence the severity of this disease. The increased frequency of Tregs has been shown to contribute to the suppression of infiltrating cytotoxic T cells in human cancerous lesions allowing these tumors to escape immunosurveillance (7) . Several types of CD4 þ
Tregs have been described, including CD4
þ natural Tregs (nTregs) that express the transcription factor Forkhead box P3 (Foxp3) and the high-affinity interleukin (IL)-2 receptor a-subunit (CD25), but fail to express the a-subunit of the high-affinity receptor for IL-7 (CD127). They are phenotypically defined as CD4 þ CD25 þ Foxp3 þ CD127 low/À T cells (6) . nTregs develop within the thymus and exert their suppressive activity by several mechanisms as recently reviewed (25) . Adaptive Tregs (aTregs) share the same phenotype as nTregs (26) ; however they may also show reduced or absent CD25 and Foxp3, as described in Tr1-like CD4 þ T cells (6, 20, 21) . aTregs are generated in the periphery from naive T H 0-like T cells following antigen exposure and a T H 2-like cytokine micromilieu, and they suppress T-cell function by their production of immunosuppressive cytokines such as IL-10 and TGFb (26) . Tregs may accumulate within papillomas either by internal proliferation, as reported in other tissues (26) , or by their continued ingress from the blood because they express CCR4, and papillomas express the CCR4 ligands CCL17 and CCL22, that would enable the retention of Tregs in these tissues (7, 18) . Although a detailed analysis of Treg trafficking was not the focus of our studies, it is interesting to speculate from our data that the robust and comparable expression of CCL22 by papillomas, clinically normal autologous laryngeal tissues, and laryngeal tissues from controls without RRP is important in regulating upper airway homeostasis by the recruitment of anti-inflammatory Tregs into the airway (18) . In contrast, recent observations in breast and ovarian cancer showed that CCL22 was differentially expressed by tumors compared with normal tissue (27, 28) . Similar observations were also described in the nasal mucosa of patients with allergic rhinitis, compared with nonatopic controls (29) . These differences suggest that the effect of CCL22 is site specific and may elicit beneficial (airway patency), or harmful outcomes (malignancy), by attracting Tregs and/or T H 2-like T cells into different tissues.
Interestingly, we found CCL17 to be differentially expressed by papillomas in RRP, compared with both, autologous laryngeal tissue and control laryngeal tissue from patients without RRP (Fig. 3) . These results suggest that active HPV infection in the larynx induces CCL17 expression and likely supports the infiltration of both T H 2-like T cells (1) (2) (3) (4) and Tregs into papillomas.
There are several mechanisms in respiratory papillomas that could induce the generation and/or expansion of Tregs. We previously showed that IL-10 and TGFb are expressed in papilloma lesions (1) . The involvement of these cytokines in generating, activating, and expanding Tregs from naive CD4 þ T cells that differentiate into Foxp3 expressing aTreg following engagement of their T-cell receptors has been documented (7, 30 (6) . In studies using FoxP3-GFP knock in mice, the expression of Foxp3-GFP correlated with suppressor activity irrespective of CD25 expression (34) . It has also been suggested that CD4 Fig. 2C and  D) . Importantly, the frequency of Helios high Tregs in papillomas was lower than in the blood of the same RRP patient (Fig. 2C and D) . This suggests that the papilloma microenvironment is conducive to de novo generation of aTregs from T H 0-like T cells. Novel therapies aimed at destabilization of Foxp3 expression on Tregs in papillomas may benefit RRP patients by blocking Treg function and thereby restoring effective T H 1-like responses in these premalignant lesions.
Our studies also showed that a large population of CD4 þ Foxp3 À cells (non-Tregs) in papilloma TILs lacked, or had reduced CD127 and CD25 expression. Expression of IL-7 and IL-2 receptors regulate naive and memory T-cell homeostasis, proliferation, and differentiation (39) . The
varied. This population can include Tr1-like T cells and previously activated, but exhausted, effector memory T cells (6, 8, 10, 20, 21) . The expansion of this population has been shown to be an index of dysfunction in CD4 þ cells from HIV-infected individuals (13) and was linked to enhanced, tumor-specific, CD4 þ T-cell apoptosis (19) .
À fraction isolated from papilloma TIL did not suppress autologous PBMC proliferation. In addition, in a single experiment, this TIL fraction failed to express IL-10, TGF-b, or IFN-g mRNA after anti-CD3 and anti-CD28 antibody stimulation (data not shown). Thus, we suspect that this TIL subpopulation contains chronically activated T cells that express CD69 þ and PD-1 high and represent dysfunctional effector T cells, as described in other diseases (9, 19) .
Our observations that CD3 þ T cells isolated from papillomas expressed PD-1 brightly (Fig. 5A ), but not PD-L1, identified by flow cytometry (data not shown), and that papillomas express both PD-1 ligands (PD-L1 and PD-L2; Fig. 5B ), suggest that the PD-1/PD-L1/L2 pathway may also contribute to the immunosuppressive milieu in papillomas. PD-L1 is expressed on a wide variety of tissues and tumors, and both PD-L1 and PD-L2 are expressed on professional antigen-presenting cells (11) . High levels of PD-L1 expressed by tumor cells have been correlated with an unfavorable prognosis in cancer (40) . PD-1 is a major regulator of CD8 þ T-cell exhaustion and viral control in chronic infection and tumor progression, and it has become an important potential therapeutic target in these diseases (41, 42) . However, the PD-1/PD-1L pathway in CD4 þ effector T-cell and Treg function is more controversial, and the mechanisms that regulate exhaustion in PD1 þ CD4 þ and PD1 þ CD8 þ T cells may differ between the these 2 cell types in adaptive cellular immunity (9, 19, (43) (44) (45) . In addition, conflicting reports of the role of PD-1 on CD4 þ Treg function suggested that PD-1-PD-L1 ligation on CD4 þ Tregs supported Treg stability and expansion (40, (46) (47) (48) , whereas others suggested that this pathway inhibited Treg expansion and suppressive function (49, 50) . Further studies are needed to determine how nTreg or aTreg stability, expansion, and function, are modulated by interactions between PD-1 and its ligands in RRP and in various tumors at different anatomic sites. 
